PHARVARIS N V's ticker is PHVS and the CUSIP is N69605108. A total of 22 filers reported holding PHARVARIS N V in Q1 2023. The put-call ratio across all filers is - and the average weighting 1.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $91,958,479 | +37.8% | 4,406,252 | 0.0% | 1.42% | +35.0% |
| Q2 2023 | $66,710,655 | +242.2% | 4,406,252 | +82.1% | 1.05% | +365.0% |
| Q1 2023 | $19,494,349 | -28.4% | 2,420,155 | 0.0% | 0.23% | -37.2% |
| Q4 2022 | $27,226,744 | +46.7% | 2,420,155 | 0.0% | 0.36% | +64.4% |
| Q3 2022 | $18,563,000 | -65.3% | 2,420,155 | 0.0% | 0.22% | -68.6% |
| Q2 2022 | $53,485,000 | +21.9% | 2,420,155 | 0.0% | 0.70% | +74.1% |
| Q1 2022 | $43,890,000 | +26.0% | 2,420,155 | 0.0% | 0.40% | +49.1% |
| Q4 2021 | $34,826,000 | -18.8% | 2,420,155 | 0.0% | 0.27% | +7.2% |
| Q3 2021 | $42,909,000 | -4.8% | 2,420,155 | 0.0% | 0.25% | -21.3% |
| Q2 2021 | $45,087,000 | -33.4% | 2,420,155 | 0.0% | 0.32% | -59.8% |
| Q1 2021 | $67,716,000 | – | 2,420,155 | – | 0.79% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 3,743,450 | $78,125,802 | 43.39% |
| venBio Partners LLC | 4,264,672 | $89,003,705 | 25.24% |
| Bain Capital Life Sciences Investors, LLC | 4,784,674 | $99,856,146 | 11.17% |
| 5AM Venture Management, LLC | 587,600 | $12,263,212 | 3.53% |
| VR Adviser, LLC | 1,563,513 | $32,630,516 | 3.44% |
| Novo Holdings A/S | 1,329,325 | $27,743,013 | 2.05% |
| Cormorant Asset Management, LP | 1,361,460 | $28,413,670 | 1.66% |
| GENERAL ATLANTIC, L.P. | 4,406,252 | $91,958,479 | 1.42% |
| Foresite Capital Management V, LLC | 33,142 | $691,674 | 1.10% |
| Soleus Capital Management, L.P. | 343,975 | $7,178,758 | 0.66% |